Home > News > 59/Long term outcomes of percutaneous and thoracoscopic surgical ablation for atrial fibrillation in patients with continuous beat-to-beat monitoring
Atrial Fibrillation
Read Time: 2 mins

59/Long term outcomes of percutaneous and thoracoscopic surgical ablation for atrial fibrillation in patients with continuous beat-to-beat monitoring

Published Online: September 27th 2010 European Journal of Arrhythmia & Electrophysiology. 2020;6(Suppl. 1):abstr59
Authors: R Dulai (Presenting Author) - Cardiology Research Department, Eastbourne District General Hospital, East Sussex Hospitals NHS Trust, UK, Eastbourne; N Freemantle - Institute of Clinical Trials and Methodology, University College London, UK, London; C Sugihara - Maidstone and Tunbridge Wells NHS Trust, UK, Maidstone ; S Podd - The Royal Devon and Exeter NHS Foundation Trust, UK, Exeter; W Eysenck - Cardiology Research Department, Eastbourne District General Hospital, East Sussex Hospitals NHS Trust, UK, Eastbourne; M Lewis - Brighton and Sussex University Hospitals NHS Trust, UK, Brighton; J Hyde - Brighton and Sussex University Hospitals NHS Trust, UK, Brighton; R A Veasey - Cardiology Research Department, Eastbourne District General Hospital, East Sussex Hospitals NHS Trust, UK, Eastbourne; S Furniss - Cardiology Research Department, Eastbourne District General Hospital, East Sussex Hospitals NHS Trust, UK, Eastbourne; N Sulke - Cardiology Research Department, Eastbourne District General Hospital, East Sussex Hospitals NHS Trust, UK, Eastbourne
Quick Links:
Article
Article Information
Article:

Introduction: Catheter ablation has been shown to be safe and effective in reducing atrial fibrillation (AF) burden and symptoms. However, there is limited long term data using continuous monitoring to assess the actual success of catheter ablation. This study assessed the long-term outcome of AF ablation in patients with implantable cardiac devices allowing beat-to-beat analysis of arrhythmia outcomes.

Methods: 223 patients (mean age 75.9 ± 7.4, 50.9% men) who underwent catheter or thorascopic surgical ablation for symptomatic AF were studied. The techniques used were PVAC ablation (51.6%), cryoablation (16.1%), point by point (13.0%), nMARQ (12.1%) and surgical ablation (7.2%). All patients had a cardiac implantable device (109 pacemaker and 114 implantable loop recorder), and were followed up for a mean period of 735.2 ± 338.0 days, post ablation.

Results: 146 (65.5%) patients had paroxysmal AF (PAF) and 77 (34.5%) patients had persistent AF. After first ablation there was a significant reduction in AF burden (relative risk 0.91, 95% CI 0.89 to 0.94; P = <0.01). Median AF burden in PAF patients reduced from (interquartile range [IQR], 0.1%-8.08%) to 0.10% ([IQR], 0%-2.44%) at one year and this was maintained up to four-year follow up. In persistent AF patients AF burden reduced from 99.9% ([IQR], 51.53%-100%) to 0.30% ([IQR], 0%-77.25%) at one year however increased to 87.3% ([IQR], 4.25%-100%) at four years follow up (Figure 1). At first ablation there was no significant difference in AF burden reduction between the different techniques used (p=0.32). At second ablation point by point ablation was associated with greater reduction in AF burden (relative risk, 0.77 [95% CI, 0.65–0.91]; P = <0.01).

Conclusion: Ablation results in significant reductions in AF burden both acutely and over the long term when assessed using continuous device derived beat-to-beat monitoring. When second ablation was required the point-by-point technique was associated with greater reductions in AF burden than “single shot” technologies. In persistent AF, burden increased two years after ablation to near pre ablation levels by year 4 suggesting a different mechanism from PAF patients where this increase was not demonstrated.

Article Information:

Further Resources

Share this Article
Related Content In Atrial Fibrillation
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72